Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X.
J Clin Oncol. 2021 Oct 20;39(30):3340-3351. doi: 10.1200/JCO.21.00389. Epub 2021 Jul 29.
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation.
Zhang C, Wang X, Yi H, Wang Y, Yan Z, Zhou J, Yang T, Liang A, Wang Z, Ma Y, Wen Q, Gao L, Gao L, Kong P, Tan X, Jiang E, Zhang X.
J Hematol Oncol. 2024 Oct 29;17(1):103. doi: 10.1186/s13045-024-01626-6.
Donor-Recipient Chimeric Cell Transplantation as the Bridging Therapy for Mitigating Total Body Irradiation-Induced Injury.
Siemionow M, Bieda K, Stawarz K, Cyran M, Chambily L, Kusza K.
Stem Cells Dev. 2024 Jul;33(13-14):343-354. doi: 10.1089/scd.2024.0068. Epub 2024 May 23.
Lineage-specific early complete donor chimerism and risk of relapse after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
Lindahl H, Vonlanthen S, Valentini D, Björklund AT, Sundin M, Mielke S, Hauzenberger D.
Bone Marrow Transplant. 2022 May;57(5):753-759. doi: 10.1038/s41409-022-01615-8. Epub 2022 Feb 24.
Posttransplant chimeric antigen receptor therapy.
Smith M, Zakrzewski J, James S, Sadelain M.
Blood. 2018 Mar 8;131(10):1045-1052. doi: 10.1182/blood-2017-08-752121. Epub 2018 Jan 22.
Transplantation of Donor-Recipient Chimeric Cells Restores Peripheral Blood Cell Populations and Increases Survival after Total Body Irradiation-Induced Injury in a Rat Experimental Model.
Siemionow M, Cyran M, Stawarz K, Chambily L, Kusza K.
Arch Immunol Ther Exp (Warsz). 2024 May 23;72(1). doi: 10.2478/aite-2024-0009. eCollection 2024 Jan 1.
iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model.
Ishii R, Hirai T, Miyairi S, Omoto K, Okumi M, Ishii Y, Tanabe K.
Am J Transplant. 2018 Feb;18(2):328-340. doi: 10.1111/ajt.14453. Epub 2017 Sep 15.
Macrochimerism and clinical transplant tolerance.
Scandling JD, Busque S, Lowsky R, Shizuru J, Shori A, Engleman E, Jensen K, Strober S.
Hum Immunol. 2018 May;79(5):266-271. doi: 10.1016/j.humimm.2018.01.002. Epub 2018 Jan 9.
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X, Shuai Y, Han Y, Zhang N, Liu Y, Yao H, Wang X, He G, Chen D, Fan F, Chang AH, Su Y, Yi H.
Front Immunol. 2024 May 13;15:1389227. doi: 10.3389/fimmu.2024.1389227. eCollection 2024.
Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG, Edwards N, Morris EC, Mackinnon S, Thomson KJ, Peggs KS.
Br J Haematol. 2012 Feb;156(4):516-22. doi: 10.1111/j.1365-2141.2011.08944.x. Epub 2011 Dec 15.
